IBDEI064 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2652,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2652,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,2652,1,5,0)
 ;;=5^H/O Ovarian Cancer
 ;;^UTILITY(U,$J,358.3,2652,2)
 ;;=^295221
 ;;^UTILITY(U,$J,358.3,2653,0)
 ;;=V10.46^^27^240^47
 ;;^UTILITY(U,$J,358.3,2653,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2653,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,2653,1,5,0)
 ;;=5^H/O Prostate Cancer
 ;;^UTILITY(U,$J,358.3,2653,2)
 ;;=^295224
 ;;^UTILITY(U,$J,358.3,2654,0)
 ;;=V10.06^^27^240^48
 ;;^UTILITY(U,$J,358.3,2654,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2654,1,4,0)
 ;;=4^V10.06
 ;;^UTILITY(U,$J,358.3,2654,1,5,0)
 ;;=5^H/O Rectal/Anal Cancer
 ;;^UTILITY(U,$J,358.3,2654,2)
 ;;=^295208
 ;;^UTILITY(U,$J,358.3,2655,0)
 ;;=V10.52^^27^240^49
 ;;^UTILITY(U,$J,358.3,2655,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2655,1,4,0)
 ;;=4^V10.52
 ;;^UTILITY(U,$J,358.3,2655,1,5,0)
 ;;=5^H/O Renal Cancer
 ;;^UTILITY(U,$J,358.3,2655,2)
 ;;=H/o Renal Cancer^295229
 ;;^UTILITY(U,$J,358.3,2656,0)
 ;;=V10.04^^27^240^51
 ;;^UTILITY(U,$J,358.3,2656,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2656,1,4,0)
 ;;=4^V10.04
 ;;^UTILITY(U,$J,358.3,2656,1,5,0)
 ;;=5^H/O Stomach Cancer
 ;;^UTILITY(U,$J,358.3,2656,2)
 ;;=^295206
 ;;^UTILITY(U,$J,358.3,2657,0)
 ;;=V10.47^^27^240^52
 ;;^UTILITY(U,$J,358.3,2657,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2657,1,4,0)
 ;;=4^V10.47
 ;;^UTILITY(U,$J,358.3,2657,1,5,0)
 ;;=5^H/O Testicular Cancer
 ;;^UTILITY(U,$J,358.3,2657,2)
 ;;=^295225
 ;;^UTILITY(U,$J,358.3,2658,0)
 ;;=V10.83^^27^240^50
 ;;^UTILITY(U,$J,358.3,2658,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2658,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,2658,1,5,0)
 ;;=5^H/O Skin Cancer
 ;;^UTILITY(U,$J,358.3,2658,2)
 ;;=H/O Skin Cancer^295241
 ;;^UTILITY(U,$J,358.3,2659,0)
 ;;=201.90^^27^240^60
 ;;^UTILITY(U,$J,358.3,2659,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2659,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,2659,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,2659,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,2660,0)
 ;;=200.20^^27^240^64
 ;;^UTILITY(U,$J,358.3,2660,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2660,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,2660,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,2660,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,2661,0)
 ;;=202.00^^27^240^66
 ;;^UTILITY(U,$J,358.3,2661,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2661,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,2661,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,2661,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,2662,0)
 ;;=200.10^^27^240^65
 ;;^UTILITY(U,$J,358.3,2662,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2662,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,2662,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,2662,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,2663,0)
 ;;=203.00^^27^240^77
 ;;^UTILITY(U,$J,358.3,2663,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2663,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,2663,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,2663,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,2664,0)
 ;;=203.01^^27^240^79
 ;;^UTILITY(U,$J,358.3,2664,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2664,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,2664,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,2664,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,2665,0)
 ;;=V10.21^^27^240^38
 ;;^UTILITY(U,$J,358.3,2665,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2665,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,2665,1,5,0)
 ;;=5^H/O Laryngeal Cancer
